BeOne Medicines (ONC) Change in Receivables (2017 - 2026)

BeOne Medicines (ONC) has 10 years of Change in Receivables data on file, last reported at $75.3 million in Q1 2026.

• Quarterly Change in Receivables rose 136.3% year-over-year to $75.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $208.4 million (down 25.92% YoY) and the FY2025 annual result came in at $165.0 million, down 49.93% from the prior year.
• Change in Receivables grew to $75.3 million in Q1 2026 per ONC's latest filing, from -$2.3 million in the prior quarter.
• Across five years, Change in Receivables topped out at $136.5 million in Q1 2023 and bottomed at -$292.6 million in Q1 2022.
• The 5-year median for Change in Receivables is $31.9 million (2025), against an average of $26.7 million.
• The widest annual swing landed in 2022, when Change in Receivables slumped 1336.7%; it then surged 2156.77% in 2024.
• Tracing ONC's Change in Receivables over 5 years: stood at -$19.4 million in 2022, then jumped by 330.96% to $44.8 million in 2023, then jumped by 180.61% to $125.7 million in 2024, then tumbled by 101.86% to -$2.3 million in 2025, then jumped by 3317.95% to $75.3 million in 2026.
• Per Business Quant, the three latest ONC Change in Receivables figures stand at $75.3 million (Q1 2026), -$2.3 million (Q4 2025), and $93.9 million (Q3 2025).

Peer Comparison